Premium
Gene Transfer of Heme Oxygenase‐1 and Carbon Monoxide Delivery Inhibit Chronic Rejection
Author(s) -
Chauveau Christine,
Bouchet Delphine,
Roussel JeanChristian,
Mathieu Patrick,
Braudeau Cécile,
Renaudin Karine,
Tesson Laurent,
Soulillou JeanPaul,
Iyer Suhasini,
Buelow Roland,
Anegon Ignacio
Publication year - 2002
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1034/j.1600-6143.2002.20702.x
Subject(s) - heme oxygenase , intimal hyperplasia , biliverdin , medicine , transplantation , cell adhesion molecule , heme , aorta , genetic enhancement , cancer research , immunology , chemistry , biochemistry , gene , smooth muscle , enzyme
The hallmark of chronic rejection is the occlusion of the artery lumen by intima hyperplasia as a consequence of leukocyte infiltration and vascular smooth muscle cell (VSMC) migration and proliferation. Heme oxygenase‐1 (HO‐1) is a tissue protective molecule which degrades heme into carbon monoxide (CO), free iron and biliverdin. We analyzed the effects of HO‐1 gene transfer into the vessel wall using an adenoviral vector (AdHO‐1) and of CO delivery in a model of chronic allogeneic aorta rejection in rats. Carbon monoxide treatment was achieved by a new pharmacological approach in transplantation using methylene chloride (MC), which releases CO after degradation. AdHO‐1‐mediated gene transfer into aorta endothelial cells (ECs) or CO delivery resulted in a significant reduction in intimal thickness compared to untreated or noncoding adenovirus‐treated controls. Aortas transduced with AdHO‐1 or treated with CO showed a reduction in the number of leukocytes as well as in the expression of adhesion molecules, costimulatory molecules and cytokines, with the gene transfer treatment displaying a more pronounced effect than the CO treatment. Conversely, CO inhibited VSMC accumulation in the intima more efficiently than AdHO‐1 treatment. Gene transfer of HO‐1 and pharmacological manipulation of CO are novel approaches to the analysis and treatment of chronic rejection.